Gaston Geenslaan 1
Leuven 3001
Belgium
32 1 675 13 10
https://www.oxurion.com
Sector(s):
Industry:
Full-time employees: 20
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Pascal Ghoson | CEO, CFO & Executive Director | N/A | N/A | N/A |
Mr. Philippe Barbeaux Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Dr. Andy De Deene M.B.A., M.D. | Chief Development Officer | N/A | N/A | N/A |
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Oxurion NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.